<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment regimens for native valve endocarditis due to &lt;EM&gt;Staphylococcus&lt;/EM&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment regimens for native valve endocarditis due to <em>Staphylococcus</em></h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment regimens for native valve endocarditis due to <em>Staphylococcus</em></div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1" colspan="2">American Heart Association (AHA)</td> <td class="subtitle1" rowspan="2">European Society of Cardiology<span style="font-size: 13px;">*</span> (ESC)</td> <td class="subtitle1" rowspan="2">British Society for Antimicrobial Chemotherapy (BSAC)</td> </tr> <tr> <td class="subtitle2">Adult</td> <td class="subtitle2">Pediatric</td> </tr> <tr> <td class="subtitle3">Methicillin-susceptible strains<sup>¶</sup></td> <td class="subtitle3">Methicillin-susceptible strains</td> <td class="subtitle3">Methicillin-susceptible strains<sup>Δ</sup></td> <td class="subtitle3">Methicillin sensitive</td> </tr> <tr class="divider_bottom"> <td> <p>Nafcillin or oxacillin 12 g per 24 hours IV in four or six divided doses for 6 weeks</p> <p><strong>or</strong></p> Cefazolin<sup>◊</sup> 6 g per 24 hours IV in three divided doses for 6 weeks</td> <td> <p>Nafcillin or oxacillin 200 mg/kg per 24 hours IV (maximum dose: 12 g per 24 hours) in four or six divided doses for 4 to 6 weeks</p> <p><strong>or</strong></p> Cefazolin<sup>◊</sup> 100 mg/kg per 24 hours IV (maximum dose: 6 g per 24 hours) in three divided doses for 4 to 6 weeks</td> <td>Oxacillin or cloxacillin or flucloxacillin 12 g per 24 hours IV in four or six divided doses for 4 to 6 weeks <p><strong>or</strong></p> <p>Cefazolin<sup>◊</sup> 6 g per 24 hours IV in three divided doses for 6 weeks</p> <p><strong>or</strong></p> <p>Cefotaxime<sup>◊<span style="font-size: 13px;"> </span></sup>6 g per 24 hours in three divided doses</p> </td> <td>Flucloxacillin 2 g IV every 4 to 6 hours for 4 weeks</td> </tr> <tr> <td class="subtitle3">Methicillin-resistant strains</td> <td class="subtitle3">Methicillin-resistant strains<sup>§</sup></td> <td class="subtitle3">Methicillin-resistant strains<sup>Δ</sup></td> <td class="subtitle3">Methicillin resistant</td> </tr> <tr> <td> <p>Vancomycin<sup>¥</sup> for 6 weeks</p> <p><strong>or</strong></p> <p>Daptomycin ≥8 mg/kg<sup>‡</sup> per 24 hours IV once daily for 6 weeks</p> </td> <td> <p>Vancomycin<sup>¥</sup> 40 mg/kg per 24 hours IV (maximum dose: 2 g per 24 hours unless levels are inappropriately low) in two or three divided doses for 6 weeks</p> </td> <td>Vancomycin<sup>¥</sup> 30 to 60 mg/kg per 24 hours IV in two or three divided doses for 4 to 6 weeks <p><strong>or</strong> </p> <p>Daptomycin<sup>†</sup><span style="font-size: 13px;"> </span>10 mg/kg per 24 hours IV once daily for 4 to 6 weeks</p> </td> <td> <p>Vancomycin<sup>¥</sup> 1 g IV every 12 hours for 4 weeks</p> <p><strong>plus</strong></p> <p>Rifampicin 300 to 600 mg orally every 12 hours for 4 weeks</p> <p><strong>OR</strong></p> <p>Daptomycin 6 mg/kg IV every 24 hours for 4 weeks</p> <p><strong>plus </strong></p> <p>Rifampicin 300 to 600 mg orally every 24 hours for 4 weeks</p> <p><strong>or</strong></p> <p>Gentamicin 1 mg/kg IV every 12 hours for 4 weeks</p> </td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses in this table are intended for patients with normal renal function. The doses of many of these agents must be adjusted in the setting of renal insufficiency; refer to the Lexicomp drug-specific monographs for renal dose adjustments.</div><div class="graphic_footnotes">IV: intravenously; IM: intramuscularly; AUC: area under the concentration-time curve.<br/>* Pediatric doses (should not exceed adult doses): oxacillin, cloxacillin, or flucloxacillin: 200 to 300 mg/kg per 24 hours IV in four or six divided doses; trimethoprim-sulfamethoxazole (cotrimoxazole) 12 mg/kg trimethoprim component per 24 hours IV in two divided doses; clindamycin 40 mg/kg per 24 hours IV in three divided doses; vancomycin 40 mg/kg per 24 hours IV in two or three divided doses; daptomycin 10 mg/kg per 24 hours IV once daily.<br/>¶ Regimens for complicated right-sided and all left-sided infective endocarditis.<br/>Δ Another alternative regimen for <em>S. aureus</em> consists of trimethoprim-sulfamethoxazole (cotrimoxazole) 960 mg trimethoprim/4800 mg sulfamethoxazole per 24 hours IV in four or six divided doses for 1 week followed by 5 weeks of oral trimethoprim-sulfamethoxazole plus clindamycin 1800 mg per 24 hours IV in three divided doses for 1 week.<br/>◊ For use in patients with nonsevere penicillin allergy. Avoid cefazolin in complicating brain abscess; nafcillin is preferred.<br/>§ Consultation with a pediatric infectious disease specialist is recommended in cases of infection due to methicillin-resistant strains.<br/>¥ Vancomycin dosing in the 2015 AHA guidelines<sup>[1]</sup> consists of 30 mg/kg per 24 hours IV in two divided doses for 6 weeks, with target trough concentrations of 15 to 20 mcg/mL. Per guidelines issued in 2020<sup>[5]</sup>, vancomycin dosing consists of a loading dose: 20 to 35 mg/kg based on actual body weight, rounded to the nearest 250 mg increment and not exceeding 3000 mg; within this range, we use a higher dose for critically ill patients. The initial maintenance vancomycin dose and interval are determined by nomogram and typically consists of 15 to 20 mg/kg every 8 to 12 hours for most patients with normal kidney function. The subsequent vancomycin dose and interval adjustments are based on AUC-guided (preferred) or trough-guided serum concentration monitoring. Refer to the UpToDate topic on vancomycin dosing for sample nomogram and discussion of AUC-guided and trough-guided vancomycin dosing.<br/>‡ Daptomycin selection and dosing should be assisted by infectious diseases consultation.<br/>† Daptomycin is superior to vancomycin for<em> S. aureus</em> bacteremia with vancomycin minimum inhibitory concentration &gt;1 mg/L. Some experts recommend adding cloxacillin 12 g per 24 hours IV in six divided doses or fosfomycin 8 g per 24 hours IV in four divided doses to daptomycin in order to increase activity and avoid development of daptomycin resistance.</div><div class="graphic_reference">Data from:<br/><br/><ol>
<li>Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association. Circulation 2015; 132:1435.</li>
<li>Baltimore RS, Gewitz M, Baddour LM, et al. Infective Endocarditis in Childhood: 2015 Update: A Scientific Statement From the American Heart Association. Circulation 2015; 132:1487.</li>
<li>Authors/Task Force Members, Habib G, Lancellotti P, et al. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J 2015; 36:3075.</li>
<li>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy. J Antimicrob Chemother 2012; 67:269.</li>
<li>Rybak MJ, Le J, Lodise TP, et al. Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant Staphylococcus Aureus Infections: A Revised Consensus Guideline and Review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835.</li></ol></div><div id="graphicVersion">Graphic 81429 Version 16.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
